Phase III Study of Letrozole Versus Tamoxifen As First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group-Reference-Cited by-同舟云学术

Phase III Study of Letrozole Versus Tamoxifen As First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

Published:2004-08-01 Issue:15 Volume:22 Page:3199-3200
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Buzdar Aman U.¹

Affiliation:

1. The University of Texas M.D. Anderson Cancer Center, Houston, TX

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.99.058

Reference6 articles.

1. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

2. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

3. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

4. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy

5. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulating structural dynamics of dual drugs for CDK4 complex addressing prostate cancer;Journal of Molecular Liquids;2023-04

2. Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal–Drug Synergism in Metallodrug Design;Molecular Pharmaceutics;2023-02-20

3. Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer;Breast Cancer Research and Treatment;2021-09-13

4. Molecular mechanisms and clinical management of cancer bone metastasis;Bone Research;2020-07-29

5. Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer;Breast Cancer Management;2019-11-01